• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Thermo Fisher Scientific Deepens Investment in Asia's Biopharma Ecosystem with Expansion of Bioprocess Design Centers

    12/2/25 5:00:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials
    Get the next $TMO alert in real time by email

    New and expanded facilities provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region's rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network designed to enhance speed, efficiency and sustainability in biomanufacturing.

    Asia is an emerging global hub for biopharmaceutical innovation, driven by increased demand for biologics, vaccines and cell and gene therapies. Thermo Fisher's continued investment across the region supports this growth, enabling customers with access to world-class technologies, expertise and localized support to accelerate the delivery of life-changing therapies.

    "Asia continues to play an increasingly important role in advancing innovation across the global biopharma industry," said Daniella Cramp, Senior Vice President and President, BioProduction at Thermo Fisher Scientific. "By expanding our network in Korea, Singapore and India, we're bringing world-class infrastructure and expertise closer to our customers, helping them deliver high-quality biologics faster, more cost-effectively and more sustainably."

    Empowering Innovation Across the Region

    Thermo Fisher's tri-hub network connects leading Bioprocess Design Centers in Incheon, Hyderabad and Singapore, accelerates process development and brings Thermo Fisher's world-class expertise closer to customers throughout Asia.

    • Incheon, Korea: The newly expanded Bioprocess Design Center empowers deeper collaboration and innovation through advanced materials, technologies, and enhanced lab capabilities.
    • Hyderabad, India (Genome Valley): The new Bioprocess Design Center, developed in partnership with the Government of Telangana, offers collaborative spaces for process design, simulation and optimization. It enables customers to co-create and test bioprocesses using the latest single-use and hybrid systems, advancing India's rapidly growing biomanufacturing ecosystem.
    • Singapore: This expanded facility provides access to bench-to-pilot scale bioprocessing, expert-led training and deep collaborations with Thermo Fisher's technical teams to scale early-stage processes, supporting flexible and sustainable biomanufacturing.

    Together, these centers ensure customers have direct access to innovation, training and technical expertise, enabling agility, scalability and faster time to market for biologics production.

    Supporting Customers from Research to Commercialization

    Thermo Fisher delivers breakthrough technologies across next-generation sequencing, mass spectrometry and advanced bioprocessing systems. The company's end-to-end capabilities span life sciences, diagnostics, analytical instruments and pharma services, empowering customers throughout the biopharma value chain.

    "Through advanced manufacturing, strategic partnerships and targeted regional investments, we are redefining what is possible in biologics production," added Tony Acciarito, President, Asia Pacific and Middle East, Africa at Thermo Fisher Scientific. "We are proud to contribute to the transformation of Asia's biopharma ecosystem and help our customers bring life-changing therapies to patients across Asia and beyond."

    To learn more about Thermo Fisher's network of Bioprocess Design Centers, please visit www.thermofisher.com/bdc.

    About Thermo Fisher Scientific

    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251202632179/en/

    Media Contact Information:

    Darlene Masse

    Phone: 401-440-7011

    Email: [email protected]

    Get the next $TMO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMO

    DatePrice TargetRatingAnalyst
    12/2/2025$670.00Overweight
    Morgan Stanley
    12/1/2025$670.00Hold → Buy
    HSBC Securities
    9/11/2025$550.00Equal Weight → Overweight
    Barclays
    8/19/2025Outperform
    William Blair
    7/24/2025$510.00Buy → Hold
    HSBC Securities
    7/11/2025$590.00Sector Perform → Sector Outperform
    Scotiabank
    7/9/2025$460.00Buy → Neutral
    UBS
    1/10/2025$630.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Shafer Michael D exercised 10,725 shares at a strike of $262.39 and sold $6,435,000 worth of shares (10,725 units at $600.00) (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    11/26/25 5:24:37 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Sr. VP and CFO Williamson Stephen gifted 433 shares, decreasing direct ownership by 1% to 31,887 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    11/17/25 4:32:05 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Sr. VP and Chief HR Officer Britt Lisa P. sold $622,136 worth of shares (1,058 units at $588.26), decreasing direct ownership by 7% to 13,087 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    11/14/25 4:51:56 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    2/21/25 4:19:32 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Boxer Michael A bought $2,105 worth of shares (4 units at $526.15), increasing direct ownership by 0.03% to 13,101 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    10/6/23 4:23:51 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Thermo Fisher with a new price target

    Morgan Stanley resumed coverage of Thermo Fisher with a rating of Overweight and set a new price target of $670.00

    12/2/25 8:35:48 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Thermo Fisher from Hold to Buy and set a new price target of $670.00

    12/1/25 8:13:54 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher upgraded by Barclays with a new price target

    Barclays upgraded Thermo Fisher from Equal Weight to Overweight and set a new price target of $550.00

    9/11/25 8:36:39 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    SEC Filings

    View All

    SEC Form 144 filed by Thermo Fisher Scientific Inc

    144 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    12/2/25 10:00:46 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

    12/1/25 4:15:51 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form FWP filed by Thermo Fisher Scientific Inc

    FWP - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    11/24/25 4:51:27 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Thermo Fisher Scientific Deepens Investment in Asia's Biopharma Ecosystem with Expansion of Bioprocess Design Centers

    New and expanded facilities provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region's rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network designed to enhance speed, efficiency and sustainability in biomanufacturing. Asia is an emer

    12/2/25 5:00:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

    Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher") announced today that it has priced an offering of €2.1 billion aggregate principal amount (the "Offering") of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the "floating rate notes") at the issue price of 100.000% of their principal amount; and €1,100,000,000 aggregate principal amount of its 3.628% senior notes due 2035 (the "fixed rate notes," and together with the floating rate notes, the "notes") at the issue price of 100.000% of their

    11/24/25 9:10:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $TMO
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

    Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

    7/23/25 9:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    908 Devices Appoints Christopher D. Brown to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

    6/16/25 8:00:00 AM ET
    $AAPL
    $MASS
    $RGEN
    Computer Manufacturing
    Technology
    Industrial Machinery/Components
    Industrials

    $TMO
    Financials

    Live finance-specific insights

    View All

    Thermo Fisher Scientific Declares Quarterly Dividend

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on January 15, 2026, to shareholders of record as of December 15, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the dev

    11/6/25 4:30:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Reports Third Quarter 2025 Results

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 27, 2025. Third Quarter Highlights Third quarter revenue grew 5% to $11.12 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.27, in-line with the prior-year quarter. Third quarter adjusted EPS grew 10% to $5.79. Delivered excellent operational performance in the quarter demonstrating the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company. Advanced our proven growth strategy, launching a range of high-impact, innovative new p

    10/22/25 6:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 22, 2025

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2025 before the market opens on Wednesday, October 22, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 761271. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under

    10/1/25 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Thermo Fisher Scientific Inc (Amendment)

    SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/9/23 11:35:13 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed

    SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/10/21 11:57:23 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials